Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Reaches Study Enrollment Milestone Associated With Credit Facility
150 Patients Enrolled in Phase 3 Clinical Trial
View HTML
Toggle Summary Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001
SOLANA BEACH, Calif. , Aug. 18, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the receipt of a letter from the U.S. Food and Drug Administration (FDA) indicating the agency's
View HTML
Toggle Summary Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission
SOLANA BEACH, Calif. , May 20, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary brand
View HTML
Toggle Summary Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti
Healthy volunteer bridging study to oral metoclopramide to be completed and submitted in NDA with existing safety and efficacy data
View HTML
Toggle Summary Evoke Resubmits Gimoti™ New Drug Application to FDA
SOLANA BEACH, Calif. , Dec. 20, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S.
View HTML
Toggle Summary Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
SOLANA BEACH, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has successfully completed patient enrollment in its pivotal Phase 3 clinical trial of EVK-001, its patented nasal delivery formulation of metoclopramide for the relief of symptoms
View HTML
Toggle Summary Evoke to Participate in the Brean Capital 2015 Life Sciences Summit
SOLANA BEACH, Calif. , Nov. 10, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer , R.Ph., President and CEO will be participating in the Brean Capital 2015 Life
View HTML
Toggle Summary FDA Accepts Evoke Pharma’s NDA Resubmission for Gimoti™
PDUFA Target Goal Date is June 19, 2020 SOLANA BEACH, Calif. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the U.S.
View HTML
Toggle Summary FDA Approves Evoke’s GIMOTI™
Commercial Partner EVERSANA Prepares for GIMOTI Launch Evoke Extends Cash Runway into 2021 SOLANA BEACH, Calif. , June 19, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that
View HTML
Toggle Summary FDA Approves PDUFA Fee Waiver for Gimoti™ New Drug Application
Cash runway updated into October 2018 SOLANA BEACH, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced that the U.S.
View HTML